Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase 1 clinical trials

被引：4
|
作者：
Marshall, Mark
Barda, David
Barnard, Darlene
Cox, Karen
Diaz, H. Bruce
King, Constance
Nutter, Suzanne
Westin, Eric
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-B248
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B248
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase
    Brega, N.
    McArthur, G. A.
    Britten, C.
    Wong, S. G.
    Wang, E.
    Wilner, K. D.
    Blasina, A.
    Schwartz, G. K.
    Gallo, J.
    Tse, A. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Preclinical optimization of the Chk1/2 inhibitor AZD7762 in combination with gemcitabine in pancreatic cancer
    Parsels, Leslie A.
    Morgan, Meredith A.
    Tanska, Dania M.
    Parsels, Joshua D.
    Davis, Mary A.
    Hassan, Maria C.
    Arumugarajah, Sankari
    Hylander-Gans, Linda
    Morosini, Deborah
    Zhao, Lili
    Simeone, Diane M.
    Canman, Christine E.
    Normolle, Daniel P.
    Zabludoff, Sonya D.
    Lawrence, Theodore S.
    Maybaum, Jonathan
    CANCER RESEARCH, 2010, 70
  • [43] γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
    Rebecca Rawlinson
    Andrew J Massey
    BMC Cancer, 14
  • [44] Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
    Nair, Jayakumar
    Huang, Tzu-Ting
    Murai, Junko
    Haynes, Brittany
    Steeg, Patricia S.
    Pommier, Yves
    Lee, Jung-Min
    ONCOGENE, 2020, 39 (33) : 5520 - 5535
  • [45] Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
    Converso, Antonella
    Hartingh, Timothy
    Garbaccio, Robert M.
    Tasber, Edward
    Rickert, Keith
    Fraley, Mark E.
    Yan, Youwei
    Kreatsoulas, Constantine
    Stirdivant, Steve
    Drakas, Bob
    Walsh, Eileen S.
    Hamilton, Kelly
    Buser, Carolyn A.
    Mao, Xianzhi
    Abrams, Marc T.
    Beck, Stephen C.
    Tao, Weikang
    Lobell, Rob
    Sepp-Lorenzino, Laura
    Zugay-Murphy, Joan
    Sardana, Vinod
    Munshi, Sanjeev K.
    Jezequel-Sur, Sylvie Marie
    Zuck, Paul D.
    Hartman, George D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (04) : 1240 - 1244
  • [46] Targeted Radiosensitization by the Chk1 Inhibitor SAR-020106
    Borst, Gerben R.
    McLaughlin, Martin
    Kyula, Joan N.
    Neijenhuis, Sari
    Khan, Aadil
    Good, James
    Zaidi, Shane
    Powell, Ned G.
    Meier, Pascal
    Collins, Ian
    Garrett, Michelle D.
    Verheij, Marcel
    Harrington, Kevin J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (04): : 1110 - 1118
  • [47] γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
    Rawlinson, Rebecca
    Massey, Andrew J.
    BMC CANCER, 2014, 14
  • [48] Chk1 is essential for the development of murine epidermal melanocytes
    Smith, Joanne
    Larue, Lionel
    Gillespie, David A.
    PIGMENT CELL & MELANOMA RESEARCH, 2013, 26 (04) : 580 - 585
  • [49] Hepatic biotransformation of CHK1 inhibitor in human, monkey, and dog
    Chen, H
    Clemens, J
    Roberts, T
    Harbol, K
    DRUG METABOLISM REVIEWS, 2004, 36 : 77 - 77
  • [50] Prexasertib Checkpoint kinase 1 (Chk1) inhibitor Treatment of advanced or metastatic cancer
    Gajdosik, Z.
    DRUGS OF THE FUTURE, 2017, 42 (09) : 555 - 563
12345